drugset
drugset / Trial / NCT04116710

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

NCT04116710 ↗

Phase 1 Completed 15 enrolled Heat Biologics
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1 open-label, single center, dose escalation study to determine a safe and effective maximum tolerated dose of HS-130 in combination with viagenpumatucel-L (HS-110) for adult subjects with advanced solid tumors who are refractory to Standard of Care.

Timeline

Start
2019-10-18
Primary completion
2021-08-12
Completion
2022-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-130 Vaccine — Intramuscular
Subject Viagenpumatucel-L Vaccine — Intramuscular

Indications

neoplasm